GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (FRA:EH3A) » Definitions » Institutional Ownership

Amarin (FRA:EH3A) Institutional Ownership : 1.58% (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is Amarin Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Amarin's institutional ownership is 1.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Amarin's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Amarin's Float Percentage Of Total Shares Outstanding is 0.00%.


Amarin Institutional Ownership Historical Data

The historical data trend for Amarin's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Institutional Ownership Chart

Amarin Historical Data

The historical data trend for Amarin can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 2.81 2.08 1.95 2.01 1.76 1.83 1.85 1.60 1.58 1.58

Amarin Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Amarin (FRA:EH3A) Business Description

Traded in Other Exchanges
Address
112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.

Amarin (FRA:EH3A) Headlines

No Headlines